Supplementary Table 1. Patient characteristics of the pooled data set in relation to MMR and *BRAF* mutation status

|  |  |
| --- | --- |
|  |  |
|   | dMMR | pMMR | *BRAF*MT | *BRAF*WT |
|   | *BRAF*MT | *BRAF*WT | *BRAF*MT | *BRAF*WT | dMMR | pMMR | dMMR | pMMR |
|   | n=53 | n=100 | n=211\* | n=2713 | n=53 | n=211\* | n=100 | n=2713 |
| Sex |   |   |   |   |   |   |   |   |
| male | 25 (47%) | 66 (66%) | 119 (56%) | 1778 (65%) | 25 (47%) | 119 (56%) | 66 (66%) | 1778 (65%) |
| female | 28 (53%) | 33 (33%) | 92 (44%) | 918 (34%) | 28 (53%) | 92 (44%) | 33 (33%) | 918 (34%) |
| missing | - | 1 (1%) | - | 17 (1%) | - | - | 1 (1%) | 17 (1%) |
| Age\*\* |   |   |   |   |   |   |   |   |
| median | 69.0 | 63.1 | 65.0 | 63.8 | 69.0 | 65.0 | 63.1 | 63.8 |
| Localization of the primary tumor |   |   |   |   |   |   |   |   |
| colon | 47 (88%) | 65 (65%) | 158 (75%) | 1427 (52%) | 47 (88%) | 158 (75%) | 65 (65%) | 1427 (52%) |
| rectosigmoid | 1 (2%) | 6 (6%) | 21 (10%) | 336 (12%) | 1 (2%) | 21 (10%) | 6 (6%) | 336 (12%) |
| rectum | 1 (2%) | 25 (25%) | 29 (14%) | 867 (32%) | 1 (2%) | 29 (14%) | 25 (25%) | 867 (32%) |
| multiple tumor | - | - | - | 3 (1%) | - | - | - | 3 (1%) |
| missing | 4 (8%) | 4 (4%) | 3 (1%) | 80 (3%) | 4 (8%) | 3 (1%) | 4 (4%) | 80 (3%) |
| Performance status |   |   |   |   |   |   |   |   |
| PS0 | 26 (49%) | 45 (45%) | 105 (50%) | 1347 (50%) | 26 (49%) | 105 (50%) | 45 (45%) | 1347 (50%) |
| PS1 | 22 (42%) | 50 (50%) | 91 (43%) | 1176 (43%) | 22 (42%) | 91 (43%) | 50 (50%) | 1176 (43%) |
| PS2 | 5 (9%) | 4 (4%) | 15 (7%) | 145 (6%) | 5 (9%) | 15 (7%) | 4 (4%) | 145 (6%) |
| missing | - | 1 (1%) | - | 18 (1%) | - | - | 1 (1%) | 18 (1%) |
| Metastatic sites involved |   |   |   |   |   |   |   |   |
| one | 27 (51%) | 32 (32%) | 76 (36%) | 1087 (40%) | 27 (51%) | 76 (36%) | 32 (32%) | 1087 (40%) |
| ≥ two | 25 (47%) | 64 (64%) | 133 (63%) | 1580 (58%) | 25 (47%) | 133 (63%) | 64 (64%) | 1580 (58%) |
| missing | 1 (2%) | 4 (4%) | 2 (1%) | 46 (2%) | 1 (2%) | 2 (1%) | 4 (4%) | 46 (2%) |
|   |
| Abbreviations: wt = wild-type tumors, mt = mutant tumors, pMMR = proficient mismatch repair system, dMMR = deficient mismatch repair system |   |   |   |  |  |  |  |  |   |   |   |
| \* + 14 patients with a non-V600E *BRAF* mutation |   |   |   |   |   |   |   |   |
| \*\* the COIN patients are excluded, due to missing data |   |   |   |   |   |   |   |   |   |   |  |
|  |  |  |  |  |  |  |  |   |   |  |